Artificial intelligence (AI) is proving to be a game-changer in various industries, with one of the most significant breakthroughs being in the field of drug discovery. By leveraging AI to analyze vast amounts of biological data, researchers can predict how different chemical compounds will interact with specific targets in the body. This accelerated approach to discovering promising drug candidates has the potential to revolutionize the pharmaceutical industry.
Cambridge University spinout company, CardiaTec, is at the forefront of using AI to tackle cardiovascular diseases (CVD). With a recent $6.5 million seed round of funding, CardiaTec aims to address the pressing issue of CVDs, which are the leading cause of death globally. Founded in 2021 by biotech and bioengineering graduates, CardiaTec is led by a team of experts who are committed to leveraging AI to make groundbreaking advancements in the field of drug discovery.
One of the key challenges in drug discovery is the high cost and failure rate of developing drug candidates. CardiaTec is focused on decoding the biology of CVDs by partnering with 65 hospitals across the U.K. and the U.S. to collect human heart tissue for its research efforts. By building a comprehensive dataset encompassing various biological information, CardiaTec aims to identify novel, targeted therapeutics that could transform the treatment of cardiovascular diseases.
While drugs developed with the assistance of AI have yet to reach the market, the early success and potential of AI-driven drug discovery have garnered significant interest and investment. Startups in the pharmaceutical space, such as Xaira, Formation Bio, and Healx, have raised substantial funding to identify new drugs for various diseases. AI has enabled companies like Insilico Medicine to identify drug candidates for rare diseases and accelerate the drug development process.
CardiaTec’s unique focus on cardiovascular diseases sets it apart from other AI-driven drug discovery companies. With only 3% of active AI-first companies targeting cardiovascular diseases, CardiaTec aims to address a significant unmet need in the pharma industry. By concentrating on a disease area that is the leading cause of death worldwide, CardiaTec is well-positioned to make a meaningful impact on improving patient outcomes and advancing the field of cardiovascular medicine.
Having previously secured $1.8 million in pre-seed funding, CardiaTec’s recent $6.5 million seed round will enable the company to expand its data collection efforts, validate its therapeutic targets, and grow its team in Cambridge. The next steps for CardiaTec involve identifying and testing actual drug candidates, a process that is expected to take several years. With support from investors like Montage Ventures, Continuum Health Ventures, and other strategic partners, CardiaTec is well-equipped to lead the charge in using AI to transform drug discovery and improve patient care.